CCCC Earnings & Financial Statements
C4 Therapeutics, Inc.
$2.85
+$0.03(+1.06%)
40
Overall
60
Value
18
Tech
44
Quality
Market Cap
$350.62M
Volume
2.83M
52W Range
$1.69 - $5.17
Target Price
$13.33
CCCC earnings and financial statements: C4 Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CCCC Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $35.95M | $35.58M | $20.76M | $31.10M | $45.78M |
| Operating income | -$115.22M | -$119.61M | -$139.03M | -$129.53M | -$82.13M |
| EBITDA | -$96.50M | -$96.95M | -$121.77M | -$124.28M | -$80.25M |
| Net income | -$104.99M | -$105.32M | -$132.49M | -$128.18M | -$83.89M |
| EPS (diluted) | $-1.27 | $-1.52 | $-2.67 | $-2.62 | $-1.82 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $359.07M | $349.60M | $376.45M | $430.84M | $506.76M |
| Total liabilities | $102.49M | $133.62M | $130.34M | $141.61M | $117.16M |
| Shareholders’ equity | $256.59M | $215.99M | $246.11M | $289.23M | $389.61M |
| Cash and equivalents | $74.60M | $55.50M | $126.59M | $29.75M | $76.12M |
| Long-term debt | $53.62M | $59.98M | $65.76M | $80.17M | $41.55M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$98.69M | -$65.16M | -$106.84M | -$105.94M | -$86.97M |
| Capital expenditure | -$607.0K | -$180.0K | -$1.71M | -$5.50M | -$1.28M |
| Free cash flow | -$99.30M | -$65.34M | -$108.55M | -$111.44M | -$88.24M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CCCC | $2.85 | +1.1% | 2.83M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |